Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Bausch Health Companies Inc.
  6. Summary
    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
34.92(c) 34.77(c) 33.44(c) 36.14(c) 36.51 Last
406 573 2 904 516 557 692 698 584 146 590 Volume
-1.77% -0.43% -3.83% +8.07% +1.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 8 544 M - -
Net income 2021 -605 M - -
Net Debt 2021 21 618 M - -
P/E ratio 2021 -13,7x
Yield 2021 -
Sales 2022 8 896 M - -
Net income 2022 268 M - -
Net Debt 2022 20 111 M - -
P/E ratio 2022 28,4x
Yield 2022 -
Capitalization 10 122 M 10 122 M -
EV / Sales 2021 3,72x
EV / Sales 2022 3,40x
Nbr of Employees 21 600
Free-Float 95,6%
More Financials
Company
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic... 
Sector
Pharmaceuticals
Calendar
10/04 | 11:00amPresentation
More about the company
Ratings of Bausch Health Companies Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BAUSCH HEALTH COMPANIES INC.
09/21Toronto shares jump as Trudeau win lifts stimulus hopes
RE
09/13BAUSCH HEALTH : Files Confidentially For IPOs of Eye Care Business and Medical Aesthetics ..
MT
09/13BAUSCH HEALTH : Update regarding the B+L Separation and the Solta IPO (Form 8-K)
PU
09/13BAUSCH HEALTH COMPANIES INC. : Other Events (form 8-K)
AQ
09/09Bausch to pay $300 million in antitrust suit over diabetes drug
RE
09/08CIPHER PHARMACEUTICALS BRIEF : Announced Renewal of Normal Course Issuer Bid
MT
09/03BAUSCH HEALTH : Salix Will Share RELISTOR (Methylnaltrexone Bromide) Data At PAINWeek 2021
AQ
09/02BAUSCH HEALTH : Says Salix Will Share Relistor (Methylnaltrexone Bromide) Data At PAINWeek..
MT
09/02BAUSCH HEALTH : Salix Will Share RELISTOR« (Methylnaltrexone Bromide) Data At PAINWeek 202..
PR
09/01BAUSCH HEALTH : Announces Participation In Upcoming Investor Conferences
PR
08/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausc..
PR
08/06INSIDER TRENDS : 90-Day Buying Trend Extended with Insider Purchase of Bausch Health Compa..
MT
08/05BAUSCH HEALTH : Moody's Affirms Ratings on Bausch Health After Announcement of IPO Plan fo..
MT
08/04BAUSCH HEALTH : RBC Capital Keeps Outperform, US$41 TP on Bausch Health After Q2 Results
MT
08/04BAUSCH HEALTH : Barclays Adjusts Bausch Health's Price Target to $31 From $35, Reiterates ..
MT
More news
News in other languages on BAUSCH HEALTH COMPANIES INC.
04/29EN DIRECT DES MARCHESá : Total, STMicro, Airbus, Valneva, Unibail, Apple, Facebook, Logite..
04/29STOCK MARKET PARIS : Pour la Fed, il est urgent d'attendre
03/04UPDATE : Winst Pharming gedrukt door dollarkoers
03/04Winst Pharming gedrukt door dollarkoers
2020Behält Warren Buffett am Ende doch recht?
More news
Analyst Recommendations on BAUSCH HEALTH COMPANIES INC.
More recommendations
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | BHC | CA0717341071 | MarketScreener
Technical analysis trends BAUSCH HEALTH COMPANIES INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 28,21 $
Average target price 35,50 $
Spread / Average Target 25,8%
EPS Revisions
Managers and Directors
Joseph C. Papa Chairman & Chief Executive Officer
Thomas J. Appio President & Co-Head-Bausch Lomb International
Sam Eldessouky CFO, Chief Accounting Officer, SVP & Controller
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BAUSCH HEALTH COMPANIES INC.36.84%10 122
JOHNSON & JOHNSON4.54%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.20.08%246 246
NOVO NORDISK A/S52.07%234 070
ELI LILLY AND COMPANY36.32%208 668